|本期目录/Table of Contents|

[1]王永军 综 述,马 骁 审 校.儿童髓母细胞瘤的诊疗进展[J].天津医科大学学报,2024,30(02):180-184.[doi:10.20135/j.issn.1006-8147.2024.02.0180]
点击复制

儿童髓母细胞瘤的诊疗进展(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
30卷
期数:
2024年02期
页码:
180-184
栏目:
综述
出版日期:
2024-03-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2024)02-0180-05
作者:
王永军 综 述马 骁 审 校
(天津市儿童医院,天津大学儿童医院神经外科,天津市儿科研究所 ,天津市儿童出生缺陷防治重点实验室,天津 300134)
Author(s):
-
关键词:
髓母细胞瘤儿童脑脊液放射治疗化学治疗靶向治疗
Keywords:
-
分类号:
R651,R726
DOI:
10.20135/j.issn.1006-8147.2024.02.0180
文献标志码:
A
摘要:
髓母细胞瘤(MB)是小儿常见的中枢神经系统恶性肿瘤,起源于原始神经干细胞,并向神经元、神经胶质细胞等多种细胞分化,多位于后颅窝的小脑蚓及第四脑室。MB是一种呈浸润性生长的高度恶性肿瘤,常通过脑脊液播散至全脑及脊髓,以手术联合放、化疗为主要治疗方式,但复发率高且预后差。近年来,随着多学科联合诊疗的优化进步,MB的长期生存率明显增加。
Abstract:
-

参考文献/References:

[1] MAHAPATRA S,AMSBAUGH M J. Medullobolastoma[M]. TreatureIsland(FL):Stat Pearls Publishing,2022:1-16.
[2] MYNAREK M,VON HOFF K,PIETSCH T,et al. Nonmetastaticme-dulloblastoma of early childhood:results from the prospective clinical trial HIT-2000 and an extended validation cohort[J]. J Clin Oncol,2020,38(18):2028-2040.
[3] HALES P W,D′ARCO F,COOPER J,et al. Arterial spin labelling and diffusion-weighted imaging in paediatric brain tumours[J]. Neur-oimage Clin,2019,22:101696.
[4] KIKUCHI K,HIWATASHI A,TOGAO O,et al. Intravoxel incoherent motion MR imaging of pediatric intracranial tumors:correlation with histology and diagnostic utility[J]. Am J Neuroradiol,2019, 40(5):878-884.
[5] ESCUDERO L,LLORT A,ARIAS A,et al. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma[J]. Nat Commun,2020,11(1):5376.
[6] MERKER J D,OXNARD G R,COMPTON C,et al. Circulating tumor DNA analysis in patients with cancer:american society of clinical oncology and college of american pathologists joint review[J]. J Clin Oncol,2018,36(16):1631-1641.
[7] LIU A,SMITH K S,KUMAR R,et al. Serial assessment of measurable residual disease in medulloblastoma liquidbiopsies[J]. Cancer Cell,2021,39(11):1519-1530.
[8] SEOANE J,DE MATTOS-ARRUDA L,LE RHUN E,et al. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases[J]. Ann Oncol,2019,30(2):211-218.
[9] THOMPSON E M,BRAMALL A,HERNDON J N,et al. The clinical importance of medulloblastoma extent of resection:a systematic review[J]. J Neurooncol,2018,139(3):523-539.
[10] ZHI T,ZhANG W L,ZhANG Y,et al. Clinical features and prognosis of 21 children with medulloblastoma[J]. Int J Pediatr,2021,48(1):68-72.
[11] MICHALSKI J M,JANSS A J,VEZINA L G,et al. Children′s oncology group phase Ⅲ trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma[J]. J ClinOncol,2021,39(24):2685-2697.
[12] PACKER R J,ZHOU T,HOLMES E,et al. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy:results of children′s oncology group trial A9961[J]. Neuro Oncol,2013,15(1):97-103.
[13] ESBENSHADE A J,KOCAK M,HERSHON L,et al. A phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children withnewly diagnosed high-risk medulloblastoma(protocol POG 9631):a report from the children′s oncology group[J]. Pediatr Blood Cancer,2017,64(6):10.
[14] ABDELBAKI M S,BOUE D R,FINLAY J L,et al. Desmoplastic nodular medulloblastoma in young children:a management dilemma[J]. Neuro Oncol,2018,20(8):1026-1033.
[15] DHALL G,O′NEIL S H,JI L,et al. Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" Ⅲ:a multi-institutional,prospective clinical trial[J]. Neuro Oncol,2020,22(12):1862-1872.
[16] LEE B,MAHMUD I,POKHREL R,et al. Medulloblastoma cerebrospinal fluid reveals metabolites and lipids indicative of hypoxia and cancer-specific RNAs[J]. Acta Neuropathol Commun,2022,10(1):25.
[17] CIMMINO F,AVITABILE M,LASORSA V A,et al. HIF-1 transcription activity:HIF1A driven response in normoxia and in hypoxia[J]. BMC Med Genet,2019,20(1):37.
[18] DEOGHARKAR A,SINGH S V,BHARAMBE H S,et al. Downregulation of ARID1B,a tumor suppressor in the WNT subgroup me-dulloblastoma,activates multiple oncogenic signaling pathways[J]. Hum Mol Genet,2021,30(18):1721-1733.
[19] ACHIHA T,KIJIMA N,KODAMA Y,et al. Activated leukocyte cell adhesion molecule expression correlates with the WNT subgroup in medulloblastoma and is involved in regulating tumor cell proliferation and invasion[J]. PLoS One,2020,15(12):e243272.
[20] WIJAYA J,VO B T,LIU J,et al. An ABC transporter drives medu-lloblastoma pathogenesis by regulating sonic hedgehog signaling[J]. Cancer Res,2020,80(7):1524-1537.
[21] WANG J,SUI Y,LI Q,et al. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targetedcuraxin drug CBL-0137[J]. Cell Death Dis,2020,11(12):1029.
[22] NANTAVITHYA C,PAULINO A C,LIAO K,et al. Development of second primary tumors and outcomes in medulloblastoma by treatmentmodality:a surveillance,epidemiology,and end results analysis[J]. Pediatr Blood Cancer,2020,67(8):e28373.
[23] WASZAK S M,NORTHCOTT P A,BUCHHALTER I,et al. Spectrum and prevalence of genetic predisposition in medulloblastoma:a retrospective genetic study and prospective validation in a clinical trialcohort[J]. Lancet Oncol,2018,19(6):785-798.
[24] SURUN A,VARLET P,BRUGIERES L,et al. Medulloblastomas associated with an APC germline pathogenic variant share thegood prognosis of CTNNB1-mutated medulloblastomas[J]. Neuro Oncol,2020,22(1):128-138.
[25] LUQUE R,BENAVIDES M,DEL B S,et al. SEOM clinical guideline for management of adult medulloblastoma(2020)[J]. Clin Transl Oncol,2021,23(5):940-947.
[26] 杨平,刘亮华,邹兵,等. 基于SEER数据库分析儿童髓母细胞瘤的预后影响因素及列线图预测模型的构建[J]. 中华小儿外科杂志,2020,41(8):725-732.
[27] 中国抗癌协会小儿肿瘤专业委员会. 儿童髓母细胞瘤多学科诊疗专家共识(CCCG-MB-2017)[J]. 中国小儿血液与肿瘤杂志,2018,23(4):169-174.
[28] HAQUE W,VERMA V,BRIAN B E,et al. Prognostic role of chemotherapy,radiotherapy dose,and extent of surgical resection in adult medulloblastoma[J]. J ClinNeurosci,2020,76:154-160.
[29] COLTIN H,SUNDARESAN L,SMITH K S,et al. Subgroup and subtype-specific outcomes in adult medulloblastoma[J]. Acta Neuropathol,2021,142(5):859-871.
[30] HILL R M,RICHARDSON S,SCHWALBE E C,et al. Time,pattern,and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy:a multicentre cohort study[J]. Lancet Child Adolesc Health,2020,4(12):865-874.

相似文献/References:

[1]刘 艳,张碧丽,王文红,等.儿童肾病综合征合并真菌感染临床分析[J].天津医科大学学报,2013,19(06):496.
[2]宋国超,王雪艳,王 峥,等.天津地区儿童血清特异性IgE过敏原临床分析[J].天津医科大学学报,2014,20(06):477.
[3]卢 洁,薛海玲. 天津市区儿童肺炎支原体肺炎发病情况调查分析[J].天津医科大学学报,2015,21(02):174.
[4]刘 静,孟昭学.北京市通州区3~6岁儿童气质类型分布及气质维度特点分析[J].天津医科大学学报,2015,21(03):261.
[5]耳文元. 幼儿46,X,I(Xq)型Turner 综合征1例报道[J].天津医科大学学报,2015,21(01):58.
[6]王 瑜,郑荣秀.儿童嗜酸性胃肠炎伴血性腹水1例报道[J].天津医科大学学报,2016,22(06):491.
[7]王晓晓,周宇辉,王 倩,等.氨基末端脑钠肽前体水平对丙种球蛋白无反应性川崎病的预测价值[J].天津医科大学学报,2016,22(06):502.
 WANG Xiao-xiao,ZHOU Yu-hui,WANG Qian,et al.Predictive value of plasma brain natriuretic peptide in IVIG-resistant Kawasaki disease[J].Journal of Tianjin Medical University,2016,22(02):502.
[8]郭永盛,邹映雪,翟 嘉,等.73例儿童型塑型性支气管炎临床特征分析[J].天津医科大学学报,2017,23(05):422.
 ?[J].Journal of Tianjin Medical University,2017,23(02):422.
[9]吴 文,崔华雷,王晓晔,等.腹腔镜治疗小儿鞘膜积液疗效观察[J].天津医科大学学报,2017,23(05):462.
[10]李静,刘长山,王雪艳,等.儿童肺炎支原体肺炎肺功能改变及临床意义的探讨[J].天津医科大学学报,2018,24(03):229.

备注/Memo

备注/Memo:
基金项目 天津市医学重点学科(专科)建设项目(TJYXZDXK-040A)
作者简介 王永军(1987-),男,医师,硕士,研究方向:小儿神经外科;通信作者:马骁,E-mail:468043090@qq.com。
更新日期/Last Update: 2024-03-20